Developments Chiasma’s Mycapssa meets all endpoints in Phase 3 acromegaly trial Chiasma (NASDAQ:CHMA) reported positive top-line Phase 3 data from a pivotal trial evaluating its octreotide candidate, conditionally trade-named Mycapssa, for the treatment of acromegaly. Acromegaly is caused by the... July 23, 2019